CCAAT enhancer binding protein β has a crucial role in regulating breast cancer cell growth via activating the TGF‑β‑Smad3 signaling pathway

Cao,Jing; Wang,Meng; Wang,Tao

doi:10.3892/etm.2017.4659

CCAAT enhancer binding protein β has a crucial role in regulating breast cancer cell growth via activating the TGF‑β‑Smad3 signaling pathway

Authors:
- Jing Cao
- Meng Wang
- Tao Wang
View Affiliations

Affiliations: Department of Pharmacy, Linyi People's Hospital of Shandong University, Linyi, Shandong 276000, P.R. China, Department of Opthalmology, Linyi People's Hospital of Shandong University, Linyi, Shandong 276000, P.R. China
Published online on: June 23, 2017 https://doi.org/10.3892/etm.2017.4659
Pages: 1554-1560
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the effect of CCAAT enhancer binding protein β (C/EBPβ) on human breast cancer cells. The plasmids pCDH‑C/EBPβ and pLKO.1‑shC/EBPβ were constructed and were infected into MDA‑MB‑468 cells, to provide C/EBPβ overexpressing and C/EBPβ knockdown cells, respectively. Cell viability, cell cycle and apoptosis were observed by MTT assay and flow cytometry analysis. Protein expression levels of C/EBPβ, TGF‑β1, P‑Smad3 and Smad3 were detected by western blotting. MTT assay showed that the absorbance of MDA‑MB‑468 cells in the pCDH‑C/EBPβ group was increased, whereas that in the pLKO.1‑shC/EBPβ group was decreased, compared with the respective control at 48 and 72 h. Flow cytometric analysis indicated that the percentage of cells in the G2 phase was significantly increased in the pCDH‑C/EBPβ group (P<0.05) and decreased in the pLKO.1‑shC/EBPβ group compared with the respective control group. The proportion of apoptotic cells was decreased in the pCDH‑C/EBPβ group and increased in the pLKO.1‑shC/EBPβ group compared with the controls. The scratch‑wound assay revealed that MDA‑MB‑468 cells depleted of C/EBPβ exhibited reduced motility compared with the control cells. Moreover, western blotting demonstrated that pCDH‑C/EBPβ increased transforming growth factor (TGF)β1 and P‑Smad3 protein expression and decreased Smad3 protein expression, whereas pLKO.1‑shC/EBPβ decreased TGFβ1 and P‑Smad3 protein expression and increased Smad3 protein expression levels. The present study demonstrated that C/EBPβ has a crucial role in regulating breast cancer cell growth through activating TGF‑β‑Smad3 signaling. These findings suggest that C/EBPβ may be a potential therapeutic target for breast cancer; however, in vivo studies are required to confirm this.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
3	Osada S, Yamamoto H, Nishihara T and Imagawa M: DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem. 271:3891–3896. 1996. View Article : Google Scholar : PubMed/NCBI
4	Poli V: The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem. 273:29279–29282. 1998. View Article : Google Scholar : PubMed/NCBI
5	Ramji DP and Foka P: CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem J. 365:561–575. 2002. View Article : Google Scholar : PubMed/NCBI
6	Cortés-Canteli M, Pignatelli M, Santos A and Perez-Castillo A: CCAAT/enhancer-binding protein beta plays a regulatory role in differentiation and apoptosis of neuroblastoma cells. J Biol Chem. 277:5460–5467. 2002. View Article : Google Scholar : PubMed/NCBI
7	Cortes-Canteli M, Wagner M, Ansorge W and Pérez-Castillo A: Microarray analysis supports a role for ccaat/enhancer-binding protein-beta in brain injury. J Biol Chem. 279:14409–14417. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhu S, Yoon K, Sterneck E, Johnson PF and Smart RC: CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci USA. 99:pp. 207–212. 2002; View Article : Google Scholar : PubMed/NCBI
9	Ewing SJ, Zhu S, Zhu F, House JS and Smart RC: C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19 (Arf). Cell Death Differ. 15:1734–1744. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zahnow CA: CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Res. 4:113–121. 2002. View Article : Google Scholar : PubMed/NCBI
11	Gomis RR, Alarcón C, Nadal C, Van Poznak C and Massagué J: C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 10:203–214. 2006. View Article : Google Scholar : PubMed/NCBI
12	Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P and Fuxe J: MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 32:5614–5624. 2013. View Article : Google Scholar : PubMed/NCBI
13	Coyle-Rink J, Sweet T, Abraham S, Sawaya B, Batuman O, Khalili K and Amini S: Interaction between TGFbeta signaling proteins and C/EBP controls basal and Tat-mediated transcription of HIV-1 LTR in astrocytes. Virology. 299:240–247. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kaminska B, Wesolowska A and Danilkiewicz M: TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol. 52:329–337. 2005.PubMed/NCBI
15	Seoane J: The TGFBeta pathway as a therapeutic target in cancer. Clin Transl Oncol. 10:14–19. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang XF and Massagué J: TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 71:1003–1014. 1992. View Article : Google Scholar : PubMed/NCBI
17	Wang P, Yu J, Yin Q, Li W, Ren X and Hao X: Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway. Neurochem Res. 37:2076–2084. 2012. View Article : Google Scholar : PubMed/NCBI
18	Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, et al: USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med. 18:429–435. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kaminska B, Kocyk M and Kijewska M: TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol. 986:171–187. 2013. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Parks RM and Cheung KL: Patient pathway for breast cancer: Turning points and future aspirations. Future Oncol. 11:1059–1070. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kurzejamska E, Johansson J, Jirström K, Prakash V, Ananthaseshan S, Boon L, Fuxe J and Religa P: C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation. Oncogenesis. 3:e1252014. View Article : Google Scholar : PubMed/NCBI
23	Buck M, Poli V, Hunter T and Chojkier M: C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol Cell. 8:807–816. 2001. View Article : Google Scholar : PubMed/NCBI
24	Sebastian T, Malik R, Thomas S, Sage J and Johnson PF: C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J. 24:3301–3312. 2005. View Article : Google Scholar : PubMed/NCBI
25	Zhu S, Oh HS, Shim M, Sterneck E, Johnson PF and Smart RC: C/EBPbeta modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression. Mol Cell Biol. 19:7181–7190. 1999. View Article : Google Scholar : PubMed/NCBI
26	Aguilar-Morante D, Cortes-Canteli M, Sanz-Sancristobal M, Santos A and Perez-Castillo A: Decreased CCAAT/enhancer binding protein β expression inhibits the growth of glioblastoma cells. Neuroscience. 176:110–119. 2011. View Article : Google Scholar : PubMed/NCBI
27	Bundy LM and Sealy L: CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. Oncogene. 22:869–883. 2003. View Article : Google Scholar : PubMed/NCBI
28	Buck M, Poli V, van der Geer P, Chojkier M and Hunter T: Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP beta is required for hepatocyte proliferation induced by TGF alpha. Mol Cell. 4:1087–1092. 1999. View Article : Google Scholar : PubMed/NCBI
29	Abraham S, Sweet T, Khalili K, Sawaya BE and Amini S: Evidence for activation of the TGF-beta1 promoter by C/EBPbeta and its modulation by Smads. J Interferon Cytokine Res. 29:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
30	Abraham S, Sweet T, Sawaya BE, Rappaport J, Khalili K and Amini S: Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes. J Neuroimmunol. 160:219–227. 2005. View Article : Google Scholar : PubMed/NCBI
31	Feinberg MW, Watanabe M, Lebedeva MA, Depina AS, Hanai J, Mammoto T, Frederick JP, Wang XF, Sukhatme VP and Jain MK: Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem. 279:16388–16393. 2004. View Article : Google Scholar : PubMed/NCBI
32	Zauberman A, Lapter S and Zipori D: Smad proteins suppress CCAAT/enhancer-binding protein (C/EBP) beta- and STAT3-mediated transcriptional activation of the haptoglobin promoter. J Biol Chem. 276:24719–24725. 2001. View Article : Google Scholar : PubMed/NCBI
33	Wotton D and Massagué J: Smad transcriptional corepressors in TGF beta family signaling. Curr Top Microbiol Immunol. 254:145–164. 2001.PubMed/NCBI
34	Seoane J: Escaping from the TGFbeta anti-proliferative control. Carcinogenesis. 27:2148–2156. 2006. View Article : Google Scholar : PubMed/NCBI